Xylyx Bio is focused on addressing the critical shortage of donor organs through innovative bioengineering solutions. Their flagship product, INSPIREX® organs, represents a significant advancement in the field of organ transplantation by providing personalized human organ grafts. These bioengineered organs aim to enhance the availability of transplantable organs, addressing the alarming statistics that show over a million individuals in the U.S. are in need of life-saving organ transplants, with only a fraction receiving them each year. The company highlights the potential of bioengineering to resolve common issues that prevent donor organs from being utilized, thereby increasing the overall success rate of transplants.

In addition to their INSPIREX® organs, Xylyx Bio is involved in cutting-edge research that explores xenogeneic cross-circulation techniques for the physiological support and recovery of ex vivo human organs, such as livers and lungs. Recent studies have demonstrated the successful rehabilitation of human donor lungs that were previously considered unsuitable for transplantation, showcasing the potential of their technologies to improve organ viability and expand the donor pool. Through these advancements, Xylyx Bio aims to revolutionize the organ transplant landscape, ultimately saving more lives and providing hope to those in need of transplants.

United States

Xylyx Bio is a regenerative medicine company focused on developing innovative approaches for tissue repair and regeneration. Through expert integration of systemic physiology, Xylyx Bio translates cutting-edge regenerative biotechnologies into first-in-class products. The company is also harnessing the power of tissue-specific extracellular matrix for applications in drug discovery and screening, in vitro disease modeling, and regenerative medicine.

Regenerative medicine

SUNY Downstate Advanced Biotechnology Incubator 760 Parkside Ave, Brooklyn, New York 11226, US

Xylyx Bio

Company Details